New data from Phase III HAVEN 6 study reinforce favourable safety and efficacy profile of $RHHBY Hemlibra in people with moderate or mild haemophilia A

F. Hoffmann-La Roche Ltd Hemlibra continues to demonstrate clinically meaningful bleed control, with 66.7% of participants with moderate or mild haemophilia A experiencing zero treated bleeds at 55.6 weeks median follow-up [1] New data also reinforce Hemlibra’s favourable safety profile, with no new safety signals observed [1] There is limited information and treatment guidance on moderate and mild haemophilia A, which can lead to delayed or missed diagnoses of bleeding episodes [2] Hemlibra is approved to treat people of all ages with haemophilia A with factor VIII inhibitors in more than 110 countries and for people of …

Read the source article at Yahoo Canada Sports
2022-07-11 09:45:00